Kathryn Tsai

Ms. Kathryn Tsai

Section on Developmental Neurogenomics, National Institute of Mental Health, Bethesda, MD, 20892
+2
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MIMeltem Izzetoglu
Meltem Izzetoglu
PSPatricia A. Shewokis
Patricia A. Shewokis
Kathryn TsaiKathryn Tsai
Kathryn Tsai
Phillip DantoinPhillip Dantoin
Phillip Dantoin
KSKathryn Sparango
Kathryn Sparango
KMKatherine Min
Katherine Min
Cognitive abilities such as attention, memory, processing time, perception, and reasoning can be augmented using some type of intervention. Within the broad range of conventional and unconventional intervention methods used in cognitive enhancement, meditation is one of those that is safe, widely practiced by many since ancient times, and has been shown to reduce stress and improve psychological health and cognitive functioning. Various neuroimaging studies using functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) have shown functional and structural changes due to meditation in different types of meditation practices and on various groups of meditators. Recently, a few studies on meditation have used functional near infrared spectroscopy (fNIRS) to study the effects of meditation on cerebral hemodynamics. In this study, we examined the short-term effects of loving-kindness (LK) meditation on sustained attention using behavioral performance measures, physiological outcomes, and cognitive activity as measured by fNIRS in first-time meditators during Stroop color word task (SCWT) performance. Our results indicated that behavioral outcomes, assessed mainly on response time (RT) during SCWT performance, showed a significant decrease after meditation. As expected, physiological measures, primarily pulse pressure (PP) measured after meditation dropped significantly as compared to the before meditation measurement. For the hemodynamic measures of oxygenated-hemoglobin (HbO2), deoxygenated-hemoglobin (Hb), and total-hemoglobin (HbT), our findings show significant differences in SCWT performance before and after meditation. Our results suggest that LK meditation can result in improvements in cognitive, physiological, and behavioral outcomes of first-time meditators after a short-term session.

24 January 2025 in Nature Ecology & Evolution
Verified
Journal Article
Closed access
PDF file
ADAlex R. DeCasien
Alex R. DeCasien
Kathryn TsaiKathryn Tsai
Kathryn Tsai
SLSiyuan Liu
Siyuan Liu
ATAdam Thomas
Adam Thomas
ARArmin Raznahan
Armin Raznahan

23 October 2025 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Open access
DCDaniel S. Cheah
Daniel S. Cheah
Kathryn TsaiKathryn Tsai
Kathryn Tsai
KKKrishna Prasad Kurpad
Krishna Prasad Kurpad
YKYousra Khalid
Yousra Khalid
SMSanjay S. Mehta
Sanjay S. Mehta
Background: The benefit of oral anticoagulation (OAC) in patients with new‐onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was previously left to the physician's discretion. The aim of this study is to identify the most effective anticoagulant regimens for reducing stroke rates in POAF patients after coronary artery bypass grafting (CABG). Methods: Using the Epic Cosmos database, we included all US patients who underwent CABG without concomitant aortic/mitral valve replacement (MVR) from 2017 to 2023. Primary outcomes include demographics of POAF/non‐POAF patients and complication rates among patients without anticoagulation, on direct oral anticoagulation (DOAC), or on warfarin. Results: Of the 147,546 patients studied, 7.6% (11,336) developed POAF. At 60 days, the use of OAC for POAF was associated with a decrease in all‐cause mortality without any difference in thromboembolism rates. At 12 months, there was no difference between all‐cause mortality and thromboembolism rates between the OAC and the no anticoagulation (NA) cohorts. Conclusions: The benefit of long‐term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear, as there was no reduction in thromboembolic events with anticoagulation despite a reduction in all‐cause mortality at 60 days. No significant reduction in thromboembolic events or all‐cause mortality was exhibited at 1 year. Thus, the benefit of long‐term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear.

16 February 2026 in Women's Health
Verified
Journal Article
Open access
EEEmily Edwards
Emily Edwards
Kathryn TsaiKathryn Tsai
Kathryn Tsai
SPSuguna Pappu
Suguna Pappu
HGHeidi Gaddey
Heidi Gaddey
TNTyler B. Nofzinger
Tyler B. Nofzinger
BMBryan McConomy
Bryan McConomy
Background: Meningiomas, benign central nervous system tumors, express progesterone and estrogen receptors. Their proliferation has been associated with hormonal and demographic factors, including female sex, obesity, and race. Prior studies on oral contraceptive pill (OCP) use and meningioma risk have been limited in their analysis of the modifying effects of race, obesity, and polycystic ovary syndrome (PCOS). Objectives: To assess the association between combined OCP use and meningioma development, and to assess how race, obesity, and PCOS influence this relationship. Design: Retrospective cohort study using aggregated electronic health record data in Epic Cosmos. Methods: Women aged 13–50 from 2005 to 2023 with and without combined OCP use were identified. Patients with history of radiation, neurofibromatosis 2, progestin-only contraceptive use, and hormone replacement therapy were excluded. The cohort was then stratified by PCOS status, obesity, and race. Results: Combined OCP users saw a 40% lower risk of meningioma compared to non-users. PCOS was associated with a bidirectional effect on meningioma risk, modified by obesity. Among patients with obesity, those with PCOS had a 30% lower risk of developing meningioma compared to those without PCOS. Among non-obese patients, those with PCOS had a 108% greater risk of developing meningioma compared to those without PCOS. After adjusting for both PCOS and obesity, women with a history of combined OCP usage had 42% reduced odds of developing meningioma. When stratified by race, combined OCP use was associated with 47% decreased risk in White patients, 34% lower risk in Black patients, and 28% lower risk in Asian patients. Controlling for race overall, combined OCP use remained significantly protective, with 43% reduced odds of meningioma development. Conclusion: Findings suggest a potential protective association between combined OCP use and meningioma that remained significant after controlling for obesity, PCOS status, and race. Additionally, this study found that meningioma risk in patients with PCOS differed based on obesity status.

24 November 2025 in World Neurosurgery: X
Verified
Journal Article
Open access
ALAlexa R. Lauinger
Alexa R. Lauinger
AMAnvita Mishra
Anvita Mishra
HKHelen Kemprecos
Helen Kemprecos
Kathryn TsaiKathryn Tsai
Kathryn Tsai
VPVarshal Patel
Varshal Patel
WHWael Hassaneen
Wael Hassaneen

1 April 2025
Verified
Preprint
Open access
MNMichael Nguyen-Truong
Michael Nguyen-Truong
Kathryn TsaiKathryn Tsai
Kathryn Tsai
MRMuhammad Rana
Muhammad Rana
SMSanjay Mehta
Sanjay Mehta
JKJames Kumar
James Kumar